成人抖阴

成人抖阴 Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) today announced the launch of a new formulation of its Alzheimer's disease (AD) treatment, Aricept® Oral Jelly 3mg, Aricept® Oral Jelly 5mg, and Aricept® Oral Jelly 10mg. The new products will be available on the Japanese market from December 2.

The new formulation of Aricept®, which was granted marketing authorisation by the Japanese Ministry of Health, Labour and Welfare on July 13, 2009, is the world's first oral jelly formulation of an AD treatment. It was listed on the NHI (National Health Insurance) drug price list on November 13 this year.

AD patients often have difficulties ingesting tablets or fine granule formulations due to a decline in their ability to swallow. The new formulation, flavoured with sweet honey lemon, will be easier for such patients to take as it has the right softness that can be broken up with the tongue and swallowed without water. As the jelly comes in a cup-shaped packet, it is able to be divided up with a spoon and administered to patients according to their ability to ingest or swallow.

Aricept® is an acetylcholinesterase inhibitor developed by 成人抖阴. It increases brain levels of the neurotransmitter acetylcholine. It is the only anti-Alzheimer's drug approved in Japan and it is indicated for the treatment of all stages of AD; mild, moderate and severe. It is estimated that there are approximately 1.31 million people in Japan who currently have AD, and this number continues to rise every year along with the advancement of the aging population.

In Japan, the current Aricept® product portfolio includes film-coated tablet, fine granule, and orally disintegrating tablet formulations. Through the addition of the new oral jelly formulation that aims to further improve drug compliance among AD patients, 成人抖阴 will continue to make further contributions to increasing the benefits of patients, and their families and caregivers.

[Please refer to the following notes for product]